97 related articles for article (PubMed ID: 7812965)
1. Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors.
Webber KO; Kreitman RJ; Pastan I
Cancer Res; 1995 Jan; 55(2):318-23. PubMed ID: 7812965
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts.
Choi CW; Lang L; Lee JT; Webber KO; Yoo TM; Chang HK; Le N; Jagoda E; Paik CH; Pastan I
Cancer Res; 1995 Nov; 55(22):5323-9. PubMed ID: 7585595
[TBL] [Abstract][Full Text] [Related]
3. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
[TBL] [Abstract][Full Text] [Related]
4. L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment.
Kobayashi H; Yoo TM; Kim IS; Kim MK; Le N; Webber KO; Pastan I; Paik CH; Eckelman WC; Carrasquillo JA
Cancer Res; 1996 Aug; 56(16):3788-95. PubMed ID: 8706025
[TBL] [Abstract][Full Text] [Related]
5. Similarities in the biodistribution of iodine-labeled anti-Tac single-chain disulfide-stabilized Fv fragment and anti-Tac disulfide-stabilized Fv fragment.
Kobayashi H; Han ES; Kim IS; Le N; Rajagopal V; Kreitman RJ; Pastan I; Paik CH; Carrasquillo JA
Nucl Med Biol; 1998 May; 25(4):387-93. PubMed ID: 9639301
[TBL] [Abstract][Full Text] [Related]
6. Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc.
Kim IS; Yoo TM; Kobayashi H; Kim MK; Le N; Wang QC; Pastan I; Carrasquillo JA; Paik CH
Bioconjug Chem; 1999; 10(3):447-53. PubMed ID: 10346877
[TBL] [Abstract][Full Text] [Related]
7. Methods to avoid adverse effect of circulating antigen on biodistribution of 125I-labeled antiTac dsFv: preinjection of intact antibody versus clearance of antigen with adivin-biotin system.
Kobayashi H; Sun BF; Yoo TM; Le N; Kim MK; Paik CH; Pastan I; Waldmann TA; Carrasquillo JA
J Nucl Med; 1999 Aug; 40(8):1381-91. PubMed ID: 10450692
[TBL] [Abstract][Full Text] [Related]
8. Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv.
Carrasquillo JA; Lang L; Whatley M; Herscovitch P; Wang QC; Pastan I; Eckelman WC
Cancer Res; 1998 Jun; 58(12):2612-7. PubMed ID: 9635587
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
[TBL] [Abstract][Full Text] [Related]
10. Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen.
Kobayashi H; Sun BF; Han ES; Kim MK; Le N; Wang QC; Nelson DL; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
Jpn J Cancer Res; 1998 Apr; 89(4):436-44. PubMed ID: 9617350
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
12. Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment.
Yoo TM; Chang HK; Choi CW; Webber KO; Le N; Kim IS; Eckelman WC; Pastan I; Carrasquillo JA; Paik CH
J Nucl Med; 1997 Feb; 38(2):294-300. PubMed ID: 9025758
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points.
Kobayashi H; Le N; Kim IS; Kim MK; Pie JE; Drumm D; Paik DS; Waldmann TA; Paik CH; Carrasquillo JA
Cancer Res; 1999 Jan; 59(2):422-30. PubMed ID: 9927057
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2.
Bera TK; Viner J; Brinkmann E; Pastan I
Cancer Res; 1999 Aug; 59(16):4018-22. PubMed ID: 10463601
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment.
Wu C; Jagoda E; Brechbiel M; Webber KO; Pastan I; Gansow O; Eckelman WC
Bioconjug Chem; 1997; 8(3):365-9. PubMed ID: 9177842
[TBL] [Abstract][Full Text] [Related]
17. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of 111In- and 125I-labeled antiTac single-chain Fv recombinant immunotoxin.
Kobayashi H; Kao CH; Kreitman RJ; Le N; Kim MK; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
J Nucl Med; 2000 Apr; 41(4):755-62. PubMed ID: 10768579
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
[TBL] [Abstract][Full Text] [Related]
20. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]